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Abstract
Background
Dengue virus (DENV) infection is widespread and its disease burden has increased in past
decades. However, little is known about the epidemiology of dengue in the Middle East and
North Africa (MENA).
Methodology / Principal Findings
Following Cochrane Collaboration guidelines and reporting our findings following PRISMA
guidelines, we systematically reviewed available records across MENA describing dengue
occurrence in humans (prevalence studies, incidence studies, and outbreak reports), occur-
rence of suitable vectors (Aedes aegypti and Aedes albopictus), and DENV vector infection
rates. We identified 105 human prevalence measures in 13 of 24 MENA countries; 81 out-
breaks reported from 9 countries from 1941–2015; and reports of Ae. aegypti and/or Ae.
albopictus occurrence in 15 countries. The majority of seroprevalence studies were reported
from the Red Sea region and Pakistan, with multiple studies indicating >20% DENV sero-
prevalence in general populations (median 25%, range 0–62%) in these subregions. Fifty
percent of these studies were conducted prior to 1990. Multiple studies utilized assays
susceptible to serologic cross-reactions and 5% of seroprevalence studies utilized viral neu-
tralization testing. There was considerable heterogeneity in study design and outbreak
reporting, as well as variability in subregional study coverage, study populations, and labora-
tory methods used for diagnosis.
Conclusions / Significance
DENV seroprevalence in the MENA is high among some populations in the Red Sea region
and Pakistan, while recent outbreaks in these subregions suggest increasing incidence of
DENV which may be driven by a variety of ecologic and social factors. However, there is
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insufficient study coverage to draw conclusions about Aedes or DENV presence in multiple
MENA countries. These findings illustrate the epidemiology of DENV in the MENA while
revealing priorities for DENV surveillance and Aedes control.
Author Summary
Dengue is a mosquito-transmitted flavivirus whose global distribution and disease inci-
dence has increased in recent decades. In the Middle East and North Africa, the epidemi-
ology of dengue remains poorly characterized despite increasing reports of outbreaks and
transmission in new areas. In order to understand the evidence supporting the epidemiol-
ogy of this virus in the region and the areas in need of further research, we conducted a
systematic review of studies reporting human prevalence, incidence, and infection rates in
the virus’ main mosquito vectors, Aedes aegypti and Aedes albopictus. Among the studies
identified, the Red Sea subregion and Pakistan reported the highest seroprevalence esti-
mates for dengue. However, we encountered substantial heterogeneity in the distribution,
quality, and quantity of published studies. These findings inform future research and sur-
veillance priorities for DENV in the MENA region.
Introduction
Dengue virus (DENV) is a globally distributed flavivirus with nearly 400 million estimated
annual infections and a growing geographic distribution and disease burden [1–3]. DENV has
a historic presence in the Middle East and North Africa (MENA), with outbreaks of dengue
and dengue-like disease reported across much of the Eastern Mediterranean region in the 19th
and early 20th centuries [4, 5]. Today, DENV may be resurging in the MENA [6, 7], with recent
outbreaks of unprecedented or previously unrecognized magnitude occurring in the Arabian
Peninsula and Pakistan [8, 9], and a 2015 outbreak in Egypt that occurred following a decades-
long absence of reported cases from that country [10]. Still, despite increasing global concern
about the threat of Aedes-transmitted arboviruses, the epidemiology of DENV in the MENA
region remains largely uncharacterized.
Understanding the epidemiology of DENV in the MENA represents an ongoing challenge
for multiple reasons [11]. Inadequate human and vector surveillance, non-reporting of illness
syndromes, and poor diagnostic capacity limit DENV detection in many countries, resulting
in delays in outbreak recognition and sparse data with which to estimate disease burden and
infection rates [12–14]. Case series, outbreak reports, and national notification reports, which
contribute much to the epidemiologic knowledge of DENV, may also contain bias in reflecting
only those areas with sufficient capacity to detect and report DENV when it occurs [1]. More-
over, clinical diagnosis of DENV infection in the absence of laboratory confirmation is often
unreliable [12, 15–18]. Cross-sectional serologic surveys for DENV exposure have the potential
to shed light on the broader population burden of DENV without these biases. However, sero-
logic cross-reactions among antibody-based assays for flaviviruses can limit the reliability of
such studies in the absence of confirmatory testing, though the latter is difficult to perform
and often unavailable [19, 20].
To further the knowledge of the epidemiology of DENV in the MENA, we undertook a
comprehensive summary and appraisal of published DENV prevalence, incidence, vector
infection rates, reported outbreaks, and Aedes occurrence reports in the MENA region. This
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report aims to enhance the understanding of the epidemiology of DENV in the MENA while
informing priorities for future research.
Materials and Methods
Objectives
The objective of this study was to characterize the epidemiology of DENV in the MENA region
through a systematic review of human prevalence and incidence studies and infection rates in
Aedes mosquitoes. We also aimed to summarize reported human outbreaks and Ae. aegypti
and Ae. albopictus occurrence in the region. The original search was last updated on December
9, 2015.
Eligibility criteria
Table 1 displays the eligibility criteria. In brief, studies containing primary prevalence, inci-
dence, and vector infection rates for DENV in the MENA region were considered eligible for
the systematic review. Publication year was not considered an inclusion criterion, as we rea-
soned that the historic distribution of DENV could be useful in understanding its current epi-
demiology by depicting ecologically viable regions in which DENV transmission continues to
occur or could re-emerge. For incidence studies, those that reported the number of acute
infections or seroconversions over any time interval were eligible. Vector infection rate studies
were included if they contained a measure of the estimated proportion of infected Ae. aegypti
or Ae. albopictus at a given time and setting in the MENA region.
Outcomes
For the systematic review, the primary outcomes were DENV human prevalence, incidence,
and vector infection rates in the MENA region. Secondary outcomes were reports of dengue
outbreaks and vector occurrence.
Data sources and search strategy
We conducted a systematic search for DENV in the MENA following Cochrane Collaboration
guidelines [21] and reported our findings using the Preferred Reporting Items for Systematic
reviews and Meta-analyses (PRISMA) guidelines [22]. The PRISMA checklist is found in S1
Fig and our search criteria in S2 Fig. Briefly, we searched PubMed, Embase, the World Health
Organization (WHO) Index Medicus for the Eastern Mediterranean Region and WHO Afri-
can Index Medicus without publication date or language restrictions, using text and MeSH/
Table 1. Criteria for study inclusion or exclusion.
Study type Inclusion Criteria Exclusion Criteria
Human prevalence/
incidence
publication
characteristics
Full article or abstract published in any year, language, setting,
or population in the MENA region; any seroconversion interval
for incidence studies
Case reports, case series, editorials, letters to editors, reviews,
commentaries, qualitative studies, basic science research studies,
studies from countries outside the MENA region
study design Any randomized or non-randomized design Non-empirical research/modelled data
outcomes DENV seroprevalence or prevalence of laboratory-confirmed
infection; DENV incidence (by any laboratory method)
No human prevalence or incidence measure reported
Vector infection
rate
Reported Ae. aegypti or Ae. albopictus infection rates by any
laboratory method
Basic science research studies, infection rates in other mosquito
species or non-MENA country
doi:10.1371/journal.pntd.0005194.t001
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Emtree terms exploded to include all subheadings. Our review covered the 23 countries
included in the MENA definitions of the WHO/EMRO, World Bank, and the Joint United
Nations Programme on HIV/AIDS (UNAIDS) for consistency with earlier regional analyses of
various infectious diseases including HIV [23].
Study selection
For each search, titles and abstracts were imported into Endnote (Thompson Reuters, Phila-
delphia, PA, USA), duplicates were removed, and were screened by one author (JH) with
potential eligibility determined by consensus with a second author (NC) when eligibility was
unclear. Full texts of potentially relevant records were retrieved and assessed for eligibility,
contacting the author of the report as necessary. Reference lists of all potentially eligible articles
and reviews were also searched. In this study, ‘report’ refers to the document (paper, abstract,
or public health record) containing an outcome measure of interest, while ‘study’ refers to the
outcome measure(s) within that report. Hence, reports could contribute more than one study,
though multiple reports of the same study were counted only once.
Data Extraction and Synthesis
Data were extracted by one of the authors (JH) using a pre-piloted data extraction form and
entered into a database created in Microsoft Access. Data from reports in English were extracted
from the full texts, while reports in French (n = 6), Turkish (n = 3), Dutch (n = 1), and German
(n = 1) were extracted from the abstracts and full texts with the help of online language software
and French, Turkish, and German language speakers [24]. There were no records in other lan-
guages. Studies were compiled by country and organized by year, using separate tables for
human prevalence, incidence, and vector infection rates. Prevalence studies were further strati-
fied as follows: 1) general prevalence studies measuring the prevalence of anti-DENV antibodies
among populations without acute infection (e.g. DENV exposure); and 2) acute DENV infection
studies assessing the prevalence of laboratory-confirmed DENV infection in those with a) undif-
ferentiated acute febrile illness (AFI) and b) suspected DENV infection (Table 2). These stratifi-
cations were made because of the different study aims and probabilities of having laboratory
evidence of DENV infection in each of these populations. Finally, the geographic distribution of
all included prevalence studies were mapped according to the first-level administrative division
(e.g. state, province) in which each study was conducted (Tableau Software, Seattle, WA, USA).
Risk of bias assessment
In order to gain a better understanding of the quality of prevalence studies identified through
the systematic review, the risk of bias (ROB) was assessed for each study based on the
Table 2. Definitions of human prevalence study populations identified through the systematic review.
Study Population Definition
General
prevalence
Seroprevalence studies reporting anti-DENV IgG prevalence measures among
individuals not suspected to have acute dengue infection, including community
members, blood donors, military, students, and hospitalized patients and outpatients
receiving care for non-febrile illnesses.
Acute DENV
infection
Undifferentiated acute febrile illness (AFI): studies for which acute dengue
infection is not differentiated by clinical grounds alone; IgG prevalence measures
obtained during the acute phase of illness is these studies are presumed to reflect
secondary infection.
Suspected dengue infection: studies in which defined or undefined clinical criteria
for probable dengue infection is stated as an inclusion criterion in the study.
doi:10.1371/journal.pntd.0005194.t002
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Cochrane approach [25] and by evaluating the precision of the reported measures. The meth-
odology for this assessment is similar to that which we have previously developed for reviews
of HIV and hepatitis C prevalence in the MENA region [26–28]. Each DENV prevalence mea-
sure was considered to have a low, high, or unclear ROB in three domains: sampling method-
ology, DENV infection ascertainment, and response rate. The latter was defined as the number
of tested individuals divided by the number of persons invited to participate in the study [29].
ROB was considered low if (1) sampling was probability-based (i.e. using some form of ran-
dom selection), (2) DENV prevalence measures included viral neutralization testing (VNT)
for general prevalence studies or biological assays (i.e. cell culture, PCR, and NS1 ELISA) for
acute infection studies, and (3) response rate was80%. Studies with missing information for
any of the domains were classified as having unclear ROB for that specific domain. Sampling
strategy was not evaluated for acute infection studies because these studies enrolled individuals
presenting to a health facility with acute infection, hence, no population-based sampling is
needed to capture this population. Studies were considered to have high precision if the num-
ber of individuals tested was 100. We considered this to be a reasonably sensitive cutoff for
precision given the heterogeneous epidemiology of DENV across the region (e.g. a prevalence
of 1% entails a 95% CI of 0–3%).
DENV outbreaks and Aedes distribution
To supplement the epidemiologic data gathered through the systematic search, reported out-
breaks and Ae. aegypti or Ae. albopictus occurrence in the MENA were also sought from the
articles retrieved through the search databases as well as through ProMED-MENA and Google
Scholar. Given that the characteristics and definitions of dengue outbreaks in the literature are
implicitly variable and that there is currently no consensus on how to define such events [30],
we broadly included any outbreak report if the author of the report defined the event as an out-
break. Multiple reports of the same outbreak were recorded only once. We manually marked
the location of reported outbreaks on the map as well, designating one mark per each first-
level administrative division in which one or more outbreaks were identified. In a separate
map, we mapped the country-level occurrence of Ae. aegypti and Ae. albopictus in order to fur-
ther inform the existing or potential epidemiology of DENV in the MENA.
Results
Search results
The selection process based on PRISMA guidelines is illustrated in Fig 1 [22]. Briefly, the
DENV search yielded 1,258 citations, 91 of which were ultimately eligible for inclusion in the
study following the addition of 4 reports identified from the bibliographies of relevant reports
and reviews. Four studies from the 1970-80s were excluded that contained DENV seropreva-
lence of 0–11% in wild and domestic animals in Pakistan, Tunisia, and Turkey, though these
may have represented cross-reactions with other flaviviruses [31–34].
Characteristics of included studies
A total of 105 human prevalence studies for DENV were identified from eligible reports
(Table 3). These studies covered 13 of 24 MENA countries and were conducted from 1962–
2015. The geographic distribution of these studies is illustrated in Fig 2, and Table 4 contains a
frequency summary of these studies. Anti-DENV antibodies were detected in 12 of 13 coun-
tries in which studies were reported with a single 1973 study from Libya reporting 0% sero-
prevalence [35]. The highest number of studies were reported from Pakistan (n = 32) and
Dengue in the MENA
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Sudan (n = 16), most of which targeted populations with acute DENV infection (undifferenti-
ated AFI or suspected dengue infection). Among general population studies, IgG prevalence
measures ranged from 0% to 61% and were reported from Djibouti (n = 4, 0–21%), Egypt
(n = 4, 0–7%), Iran (n = 3, 0–7%), Kuwait (n = 3, 0–56%), Lebanon (n = 3, 0–61%), Pakistan
Fig 1. PRISMA flow diagram of article selection. Flow diagram for dengue prevalence, incidence, and vector infection rates in the
Middle East and North Africa.
doi:10.1371/journal.pntd.0005194.g001
Dengue in the MENA
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Table 3. Human prevalence studies for dengue virus in the Middle East and North Africa (n = 105).
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
make†
Target
Protein
Assay
serotype
Sample
size
Prevalence Additional
testing&
Comments
Afghanistan (n = 1)
Elyan [44] 2008–
10
Uruzgon,
Helmand,
Kandahar
Hospital; AFI
patients (20–
59)
Conv. ELISA PanBio Env 1–4 913 19.2%** 2.6% (8/312)
were IgM+;
observed
cross-reaction
to WNV, TBEV
Djibouti (n = 6)
Salah [45] 1987 Djibouti City Military;
healthy
soldiers
Conv. IIFA In-house wv 2 50 0%
Randa Rural
community;
general pop.
Conv. IIFA In-house wv 2 69 0%
Djibouti City Hospital; AFI
patients
Conv. IIFA In-house wv 2 41 0%
Rodier [37] 1991 Djibouti City Clinical
setting; AFI
patients (1–55)
Conv. ELISA
IgM
In-house wv 1 91 7.7%** 3.7% (1/27)
were VNT+;
multiple
observed
cross-
reactions
Conv. ELISA
IgM
In-house wv 2 same 25.2%** 11.1% (3/27)
were VNT+;
multiple
observed
cross-
reactions
Conv. ELISA
IgM
In-house wv 3 same 16.4%** multiple
observed
cross-
reactions
Conv. ELISA
IgM
In-house wv 4 same 18.7%** multiple
observed
cross-
reactions
Fauld [46] 2011 Djibouti City Animal
quarantine
station;
workers
Conv. IIFA EuroImmun wv 1–4 10 10.0%** not cross-
reactive to
WNV
Andayi [47] 2010–
11
Djibouti City Community;
general pop.
(<1–100)
SRS ELISA PanBio Env 1–4 911 21.8%
Egypt (n = 5)
Mohammed
[48]
1966 Abyss rural
community;
general pop.
Conv. HI In-house wv 1 29 7.0%** possible cross-
reaction to
WNV
HI In-house wv 4 same 3.0%** possible cross-
reaction to
WNV
Alexandria urban
community;
general pop.
Conv. HI In-house wv 1 55 4.0%** possible cross-
reaction to
WNV
(Continued )
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Table 3. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
make†
Target
Protein
Assay
serotype
Sample
size
Prevalence Additional
testing&
Comments
HI In-house wv 4 same 5.0%** possible cross-
reaction to
WNV
Mohammed
[49]
1968 Alexandria Hospital; AFI
patients (3–13)
Conv. HI, CF In-house wv 1 120 0%** 0% (0/48)
were
convalescent +
Alexandria Clinical
setting; adults
Conv. HI In-house wv 1 78 0%
Darwish [50] 1969 Multiple University;
students
Conv. HI In-house wv 1 1133 0.3%
Iran (n = 4)
Saidi [51] 1970 Multiple n/s n/s HI In-house wv 1,2,3 394 6.0%** possible cross-
reaction to
WNV
Saidi [52] 1970–
71
Caspian
region
Community;
children (1–6)
Conv. HI In-house wv 2 100 0%
Chinikar
[53]
2000–
12
Countrywide Clinical
setting; AFI
patients
Conv. ELISA Vircell wv 1,2 300 3.3% 3.3% (10/300)
were IgM+;
DEN-1,2 were
positive by
PCR
Aghaie [14] 2014 Sistan-
Baluchestan
blood donor
center; general
pop.
Conv. ELISA PanBio Env 1–4 540 7.6% 78% (32/41)
ELISA+ were
IFA+
Kuwait (n = 8)
Ibrahim [54] 1966–
68
Multiple Multiple
settings; blood
donors, non-
AFI patients,
children (1–60)
Conv. HI In-house wv 1 627 6.5%** not cross-
reactive to
DEN-2 or
WNV
HI In-house wv 2 same 8.1%** not cross-
reactive to
DEN-1 or
WNV
Al-Nakib
[55]
1979–
82
Jabriya Hospital; non-
AFI patients
(0–60+)
SRS HI In-house wv 1 502 3.2%** not cross-
reactive to
DEN-2 or
WNV
HI In-house wv 2 same 8.4%** all were cross-
reactive to
DEN-1, WNV,
or TBEV
Pacsa [56] 2002* Multiple n/s; Kuwaiti
nationals
n/s ELISA
and
IgG
blot
CDC and
Genlab
wv 1–4 425 13.9% only DENV
1–3 were
positive
n/s; Kuwait
Bedouins
n/s ELISA
and
IgG
blot
CDC and
Genlab
wv 1–4 47 0%
n/s;
expatriates
from South
Asia
n/s ELISA
and
IgG
blot
CDC and
Genlab
wv 1–4 266 37% only DENV
1–3 were
positive
(Continued )
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Table 3. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
make†
Target
Protein
Assay
serotype
Sample
size
Prevalence Additional
testing&
Comments
n/s;
expatriates
from
Southeast
Asia
n/s ELISA
and
IgG
blot
CDC and
Genlab
wv 1–4 31 56.6% only DENV
1–3 were
positive
n/s;
expatriates
from Middle
East
n/s ELISA
and
IgG
blot
CDC and
Genlab
wv 1–4 140 25% only DENV
1–3 were
positive
Hospital;
returned
travelers with
dengue-like
illness
n/s ELISA
IgM
PanBio Env 1–4 210 9.0% only DENV
1–3 were
positive; 10%
(2/19) IgM
+ were PCR+
Lebanon (n = 3)
Garabedian
[5]
1962–
65
Multiple Community;
general pop.
(0–41+)
SRS HI In-house wv 2 113 61.9%** observed
cross-reaction
with WNV,
YFV
Multiple Community;
general pop.
(0–41+)
SRS HI In-house wv 1 171 49.1%** observed
cross-reaction
with WNV,
YFV
Hatem [57] 1969 Beirut n/s n/s HI In-house wv 2 126 0%
n/s n/s HI In-house wv 1 same 4.0%** observed
cross-reaction
with WNV
Libya (n = 1)
Darwish [35] 1973 Sebha community
and clinic;
children, non-
AFI patients
Conv. HI In-house wv 1 148 0%
Pakistan (n = 32)
Darwish [31] 1983* Karachi Hospital;
patients
Conv. CF In-house wv 1 43 9.3%
Akram [58] 1994 Karachi Hospital; AFI
patients (<1–
12)
Conv. ELISA
IgM
In-house wv 1 92 9.8%** 12% (3/25)
additional
convalescent
sera were +;
observed
cross-reaction
to WNV
Conv. ELISA
IgM
In-house wv 2 Same 14.6%** 24% (6/25)
additional
convalescent
sera were +;
observed
cross-reaction
to WNV
Siddiqui [41] 1999–
2001
Karachi Community;
AFI patients
(<16)
Conv. ELISA
IgM
Diag. Auto. wv 1–4 341 15.8%
(Continued )
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Table 3. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
make†
Target
Protein
Assay
serotype
Sample
size
Prevalence Additional
testing&
Comments
Tariq [59] 2003 Mangla,
Mirpur
Community;
suspected
dengue
Conv. ELISA
IgM
In-house n/s n/s 52 73%
Jamil [60] 2005 Karachi Hospitals;
suspected
dengue
Conv. ELISA
IgM
Chemicon n/s n/s 106 36.8%
Khan [61] 2006 Karachi Hospital;
suspected
dengue (2–72)
Conv. ELISA
IgM
PanBio Env 1–4 83 83.6%
Conv ELISA
IgM
Calbiotech PA 1–4 same 50.7% 87.8% (73/83)
were PCR+ for
DEN-2,3 only
Khan [62] 2006 Karachi Hospital;
suspected
dengue
Conv. ELISA PanBio Env 1–4 250 23.2% 53.6% (134/
250) were IgM
+; 74% (185/
250) were
PCR+ for
DEN-2 or 3
Koo [63] 2006–
11
Multiple Clinic settings;
suspected
dengue
Conv. PCR In-house 2,3 200 47% none were
DEN-1 positive
Khan [64] 2006–
07
Hyderabad Hospital;
suspected
dengue (13–
70)
Conv. ELISA
IgM
In-house n/s n/s 50 40%
Khan [65] 2006–
07
Multiple Hospital;
suspected
dengue
Conv. ELISA
IgM
Calbiotech PA 1–4 15,040 26.3%
Abbasi [66] 2007–
08
Karachi Hospital;
suspected
dengue
Conv. ELISA
IgM
Commercial n/s n/s 114 69.6%
Tahir [67] 2008 Lahore Hospital;
suspected
dengue
Conv. ICT
(IgM)
In-house n/s n/s 3215 54.9%
Murad [68] 2008 Shangla Community;
suspected
dengue (1–80)
Conv. ELISA
IgM
n/s n/s n/s 70 17.1%
Mahmood
[69]
2008 Lahore Hospital;
suspected
dengue
secondary
infection (age
1–80)
Conv. ELISA NovaLisa Env 1–4 200 39.5%
Hospital;
suspected
dengue
primary
infection (age
1–80)
Conv. ELISA
IgM
DRG n/s 2 341 48.7%
Kidwai [70] 2008–
09
Karachi Hospital;
suspected
dengue (>13)
Conv. ICT
(IgG)
In-house wv 1–4 599 83.2% 41.9% (251/
599) were IgM
+
(Continued )
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Table 3. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
make†
Target
Protein
Assay
serotype
Sample
size
Prevalence Additional
testing&
Comments
Zafar [71] 2009 Rawalpindi rural
communities;
adults without
history of
flavivirus
vaccination
(>18)
StRS ELISA Omega PA
(DEN-
2)
1–4 96 19.8%
Zafar [72] 2009 Rawalpindi Community;
general pop.
Conv. ELISA Omega,
Vircell
PA
(DEN-
2)
1–4 244 28.8%
Qureshi [73] 2010–
12
Karachi Hospital;
suspected
dengue
Conv. ICT
(IgM)
In-house n/s n/s 162 9.9%
Khan [74] 2010 Punjab Hospital;
suspected
dengue (4–60)
Conv. ELISA
IgM
n/s n/s n/s 125 54.4%
Hasan [75] 2010 Karachi Hospital;
suspected
dengue (>12)
Conv. ELISA
IgM
n/s n/s n/s 259 34.8%
Umar [76] 2010 Rawalpindi Hospital;
suspected
dengue
Conv. ELISA
IgM
n/s n/s n/s 500 6.8%
Jameel [77] 2010 Lahore Hospital;
suspected
dengue
Conv. ELISA
IgM
In-house n/s n/s 341 48.7%
Naeem [78] 2011 Lahore Hospital;
suspected
dengue (1–10
+)
Conv. ELISA
IgM
n/s n/s n/s 79 25.3%
Ahmed [79] 2011 Lahore Hospital;
suspected
dengue (13–
81)
Conv. ELISA
IgM
n/s n/s n/s 640 43.9%
Ijaz [80] 2011 Lahore Hospital;
suspected
dengue (<15–
60+)
Conv. ELISA n/s n/s 1–4 5,274 49%
Rashid [81] 2011 Lahore Hospital;
suspected
dengue (<18)
Conv. ELISA n/s n/s n/s 254 36.6% 53.9% (137/
254) were IgM
+
Khan [82] 2011 Lahore Hospital;
suspected
dengue (5–50
+)
Conv. ELISA In-house wv 1–4 50 72% 30% (30/50)
were IgM+;
66% (33/50)
were PCR+ for
DEN-1,2; 60%
(30/50) were
cell culture+
Hasan [83] 2007–
13
Multiple Hospitals;
suspected
Crimean-
Congo
Hemorrhagic
Fever
Conv. ELISA
IgM
PanBio Env 1–4 168 33.9% 2.3% (4/168)
were PCR+
(Continued )
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Table 3. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
make†
Target
Protein
Assay
serotype
Sample
size
Prevalence Additional
testing&
Comments
Ali [84] 2011 Khyber
Pakhtunkhwa
Clinical
settings;
suspected
dengue (<10 to
>51)
Conv. ELISA Diag. Auto. wv 1–4 612 20.2% 31.9% (195/
612) were IgM
+
Hisam [85] 2012 Rawalpindi Military
Hospital; AFI
patients
PS ELISA
IgM
n/s n/s n/s 500 3.2%
Assir [86] 2012 Lahore Hospital;
suspected
dengue (12–
90)
Conv. ELISA
IgM
GmbH wv 1–4 85 43.5% 20% (3/15)
were PCR
+ for DEN-2
Saudi Arabia (n = 11)
Fakeeh [87] 1994–
99
Jeddah Hospitals;
suspected
dengue (1-
>50)
Conv. IIFA,
HI
In-house wv 1,2 985 31.9% 16.2% (160/
985) were
ELISA IgM+;
21% (207/985)
were PCR+
(DEN-1,2,3)
Fakeeh [88] 1994–
2002
Jeddah Hospitals;
suspected
dengue
Conv. IFA, HI In-house wv 1,2,3 1020 50.5% 10.8% (110/
1020) were
ELISA IgM+;
20.5% (209/
1020) were
PCR+ (DEN-
1,2,3)
Khan [89] 2004 Makkah Hospital;
suspected
dengue (6–94)
ELISA PanBio Env 1–4 136 32.4% 58.8% (80/
136) were IgM
+; 28.1% (27/
96) were PCR
+ (DEN-2,3)
Ayyub [90] 2004–
05
Jeddah Hospital;
suspected
dengue (2–60)
Conv. ELISA
IgM
n/s n/s n/s 80 48.8%
Shahin [91] 2006–
08
Makkah Hospital;
suspected
dengue
Conv. ELISA
IgM
and/or
PCR
n/s n/s n/s 159 100%
Said [92] 2006 Jeddah Hospital;
suspected
dengue (2–71)
Conv. ELISA
IgM
In-house n/s n/s 525 19.2% % includes
paired serum
sample
Memish [93] 2010 Multiple Military; adults Conv. ELISA PanBio Env 1–4 1024 0.1% 0% of IgG
+ were IgM+
Gamil [94] 2010–
11
Jeddah Hospitals;
suspected
dengue (3–56)
Conv. n/s n/s n/s n/s 553 47.7%
Al-Azraqi
[95]
2013 Jizan Clinics; clinic
attendants (1–
60+)
SRS ELISA Focus wv 1–4 268 26.5%
Aseer Clinics; clinic
attendants (1–
60+)
SRS ELISA Focus wv 1–4 697 33.7%
(Continued )
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Table 3. (Continued)
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governorate
Setting;
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Sampling Assay
type
Assay
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Target
Protein
Assay
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Prevalence Additional
testing&
Comments
Ashshi [96] 2014 Mecca blood donation
center; adults
Conv. ELISA PanBio Env 1–4 100 7% 6% (6/100)
were IgM+;1%
(1/100) were
NS1+
Somalia (n = 7)
Botros [97] 1987 Hargeysa Refugee
camp; AFI
patients
Conv. ELISA In-house wv 2 38 60.7% acute and
convalescent
samples;
39.4% (15/38)
were IFA+;
37.9% (11/29)
were HI+;
14.2% (4/28)
were ELISA
IgM+
Kanesa-
thasan [98]
1993 n/s Military base;
AFI soldiers
Conv. ELISA
IgM
and/or
HI
n/s n/s n/s 84 17.8% 93% (14/15)
were cell
culture +
(DEN-2 and 3
only)
Sharp [99] 1992–
93
Mogadishu Military
Hospital; AFI
patients
(soldiers)
Conv. ELISA
IgM
In-house wv 1–4 129 34.9% 40.6% (39/96)
were cell
culture positive
for DEN-2; 2%
(2/96) were
cell culture
positive for
DEN-3
Baardera Military; adults
(19–25)
Conv. ELISA
IgM
In-house wv 1–4 494 7.7%** observed
cross-reaction
with WNV
Nur [100] 1995 Mogadishu Hospital;
children (<1
to > 2 years of
age)
CC. ELISA
IgM
Progen wv 2 23 0%
Hospital; AFI
patients with /
without rash
(<1 to > 2
years of age)
CC. ELISA
IgM
Progen wv 2 46 0%
Kyobe Bosa
[101]
2011 Mogadishu Hospitals; AFI
patients (20–
49)
Conv. ELISA
IgM
n/s n/s 1,2,3 134 80% 62% (83/134)
were PCR+
Sudan (n = 16)
Omer [36] 1976 Gezira Rural
community;
general pop.
(5–40+)
Conv. HI In-house wv 2 109 27.5% 17.4% (19/
109) were VNT
+
Hyams
[102]
1984 Port Sudan Hospital; AFI
patients (12–
70)
Conv. HI In-house wv n/s 100 3% 14.8% (8/54)
were
convalescent
+; 1% (1/100)
DEN-1 cell
culture +; 17%
(17/100) DEN-
2 cell culture +
(Continued )
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Table 3. (Continued)
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of
study*
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governorate
Setting;
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(age range,
years)
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type
Assay
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Target
Protein
Assay
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Sample
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Prevalence Additional
testing&
Comments
Woodruff
[103]
1986 Juba Hospital;
patients with
history of fever
within past 6
months and
AFI patients
(1–85)
Conv. HI In-house n/s n/s 130 40.0%** represents
single virus
activity not
cross-reactive
to multiple
flaviviruses
tested
McCarthy
[104]
1988 Khartoum Clinical
setting; non-
AFI patients
CC ELISA In-house wv 2 100 49% 0% were IgM+
Clinical
setting; AFI
patients (1–89)
CC ELISA In-house wv 2 196 48%** 0% were IgM+;
possible cross-
reaction to
WNV
Watts [18] 1989 Northern
Province
Clinical
setting; AFI
patients (11–
70)
Conv. ELISA In-house n/s 2 185 24.0%** possible cross-
reactions to
multiple
flaviviruses
Ibrahim
[105]
1997–
99
Khartoum Clinical
setting:
suspected
measles
Conv. ELISA
IgM
MRL Diag. n/s n/s 188 3.2%
Malik [106] 2004–
05
Port Sudan Hospitals;
suspected
dengue (<1–
15)
Conv. ELISA
IgM
PanBio Env 1–4 40 90.0% 39% (9/23)
were PCR+
(DEN-3)
Gould [107] 2005 South
Kordofan
Clinical
setting;
suspected YF
patients
(n = 3), severe
illness (n = 8),
AFI patients
(n = 7), healthy
(n = 16)
Conv. ELISA
IgM
In-house wv n/s 34 5.9%** observed
cross-reaction
with YFV,
WNV
Farnon [38] 2005 Kortalla Community;
general pop.,
YF vaccinated
(0–44+)
SSCS ELISA In-house wv 1–4 87 1.1%** observed
cross-reaction
in YF vaccine
recipient; 0%
were IgM+;
52% (45/87)
were VNT+ for
DENV and
YFV
Seidahmed
[39]
2008–
09
Port Sudan
City
Urban
community;
individuals
from houses
with DENV-
carrying
mosquitoes
(<1–80)
RSS ELISA
IgM
PanBio Env 1–4 791 5.2%
Adam [108] 2008–
09
Port Sudan
City
Hospitals;
pregnant
women with
deliveries
Ret.
cohort
ELISA
IgM
n/s n/s 1–4 10,820 0.7%
(Continued )
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Table 3. (Continued)
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Himatt [109] 2011 Kassala state Community;
general pop.
(5–75+)
MSCS ELISA PanBio Env 1–4 489 9.4% 0.6% (3/489)
were IgM+
Abdalla
[110]
2012 Kassala State Hospital; AFI
patients with
suspected
measles (2–
65)
Conv. ELISA PanBio Env 1–4 60 11.7%
Elduma [15] 2012 Port Sudan Hospital;
pregnant
women with
AFI
Conv. ELISA Commercial n/s n/s 39 12.8% 2.6% (1/39)
were IgM+ and
PCR+
Soghaier
[111]
2014 South
Kordofan
Urban and
rural
communities;
general pop.
(15–60)
MSCS ELISA PanBio Env 1–4 600 27.7% 77% of study
population
were YFV
vaccinated
Turkey (n = 6)
Ari [34] 1971 Izmir Community
and clinic;
general pop.
Conv. HI In-house wv 2 270 0%
Radda [112] 1973* Izmir n/s; general
pop.
Conv. HI In-house wv 2 270 0.3%** observed
cross-reaction
with WNV
Istanbul n/s; general
pop.
Conv. HI In-house wv 2 90 0%
Ankara n/s; general
pop.
Conv. HI In-house wv 2 95 0%
Ergunay
[113]
2010 Ankara,
Konya,
Eskisehir,
Zonguldak
blood donation
center; blood
donors
Conv. ELISA EuroImmun wv 1–4 2435 0.9% 14.2% (3/21)
of IgG+ were
IIFT+ for DEN-
2; 9.5% (2/21)
of IgG+ were
IgM+
Tezcan
[114]
2010–
11
Mersin blood donation
center; blood
donors
Conv. ELISA Vircell wv 1–4 920 16.6% 0.9% (8/920)
were IgM+; 0%
were NS1+
Yemen (n = 5)
Bin Ghouth
[115]
2011 Hadramout Hospital;
suspected
dengue (<5 to
55+)
Conv. ELISA PanBio Env 1–4 982 50.6% 64.1% (630/
982) IgM+;
86.2% (163/
189) PCR+ for
DEN-3
Malik [116] 2010–
11
Al-Hudaydah Clinical
setting; AFI
patients (0–45
+)
Conv. ELISA PanBio Env 1–4 136 87.5% 8.1% (11/136)
were IgM+
Madani
[117]
2010 Hadramout Clinical
settings;
suspected viral
hemorrhagic
fever (3–75)
Conv. ELISA PanBio Env 1–4 207 48.3% 78.7% (163/
207) IgM+;
46.9% (97/
207) NS1+;
0.09% (2/207)
PCR+ for
DEN-1,2
(Continued )
Dengue in the MENA
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005194 December 7, 2016 15 / 31
(n = 3, 9–28%), Saudi Arabia (n = 4, 0–33%), and Sudan (n = 5, 9–49%). ELISAs were the most
commonly used diagnostic method for all study types and the majority studies from the
MENA used in-house assays (Table 4). VNT results were reported in 3% (n = 3) of all studies
while observed or potential serologic cross-reactions with other flaviviruses were present in
multiple studies [36–38] (Tables 3 and 4). Three human incidence measures for DENV were
identified (Table 5): the first reported an ELISA IgM incidence of 35 cases per 10,000 people
living in urban homes in Port Sudan City, Sudan where DENV-carrying mosquitoes were
identified over an 11-month period [39]; the second reported an ELISA IgM incidence of 94
cases per 10,000 people in a general population in Port Sudan, Sudan over a 17-week period in
2010 [40]; the third reported an ELISA IgM, NS1 antigen, or PCR incidence of 185 cases per
100,000 febrile children in an urban slum in Karachi, Pakistan from 1999–2001 [41]. Three
vector infection rate studies for Ae. aegypti and Ae. albopictus were identified from Pakistan
and Yemen [42, 43] (Table 6).
Risk of bias assessment results
The quality assessment for each study is found in S1 Table and a summary of the precision
and risk of bias assessment is found in Table 4. In brief, most studies (65%) contained high
precision as defined by a sample size of100 participants. A minority (36%) of general popu-
lation seroprevalence studies utilized some form of random sampling, and response rates were
either<80% or not reported in 86% of general population studies. VNT or a biologic confir-
matory assay (i.e. cell culture, PCR, and NS1 ELISA) was performed in 5% and 36% of general
Table 3. (Continued)
Country,
Ref.
Year(s)
of
study*
City or
governorate
Setting;
population
(age range,
years)
Sampling Assay
type
Assay
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Protein
Assay
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size
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testing&
Comments
Rezza [118] 2012 Al Hudaydah Hospitals; AFI
patients with
dengue-like
illness (1–60)
CS ELISA NovaLisa Env 1–4 400 72.5% 18% (72/400)
IgM+; 13.8%
(55/400) PCR
+ for DEN-1,2
Qassem
[119]
2013 Hadramout Clinical
setting;
suspected
dengue and/or
west nile
infection
Conv. ELISA
IgM
n/s n/s n/s 42 19.0%** observed
cross-reaction
with WNV
* Indicates year of publication when year(s) of data collection not available in report.
† All serologic assays were IgG unless otherwise stated.
**Indicates documented occurrence or suspicion of false-positives due to cross-reactions with other same family viruses or low serologic titers.
Abbreviations: AFI, acute febrile illness patients; Ag, antigen; CF, complement fixation; Conv, convenience; ELISA, enzyme-linked immunosorbent assay;
HI, hemagglutinin inhibition; ICT, immunochromatography test; IIFA, indirect immunofluorescence antibody test; MSCS, multi-stage cluster sampling; n/s,
not specified; NS1, NS1 antigen test; PA, purified antigen; PCR, polymerase chain reaction; pop., population; PS, purposive sampling; RSS, random
stratified sampling; SRS, simple random sampling; SSCS, single stage cluster sampling; VNT, viral neutralization test
Assay Abbreviation: CDC (Centers for Disease Control and Prevention, USA); Chemicon (Chemicon, Temecula, CA, USA); Diag. Auto. (Diagnostic
Automation, CA, USA); DRG (DRG International Inc); Euroimmun (Lubeck, Germany); Focus (Focus Diagnostics, Cypress CA, USA); Genlab (Genlab
Diagnostics, Singapore); GmbH (Human GmbH, Wiesbaden, Germany); MRL Diagnostics (Cypress CA, USA); NovaLisa (Dietzenbach, Germany); Omega
(Omega Diagnostics, Scotland, UK); PanBio (Brisbane, Australia); Progen (Heidelberg, Germany); SD Bioline (Standard Diagnostics, Korea); Vircell (Vircell
Microbiologists, Granada, Spain)
doi:10.1371/journal.pntd.0005194.t003
Dengue in the MENA
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005194 December 7, 2016 16 / 31
population seroprevalence and acute DENV infection studies, respectively, entailing low ROB
for the assays used.
Dengue outbreaks and Aedes occurrence
Reported outbreaks of DENV in the region were gathered through citations collected from the
search databases (S2 Table) and mapped along with the geographic distribution of prevalence
studies in Fig 2. For DENV, 81 outbreaks were reported from 9 countries in the region from
1941–2015, including sentinel reports of autochthonous transmission in Egypt (2010) and
Yemen (1983). Reports contained variable descriptions of outbreaks including ‘estimated’, ‘sus-
pected’, ‘reported’, and/or laboratory ‘confirmed’ cases (S2 Table). The definition that qualified
each event as an outbreak was unclear in most instances. Outbreaks of DENV serotypes 1–3
were reported from countries surrounding the Red Sea and DENV-4 was only reported from
Pakistan [120, 121]. Although, in general, DENV serotypes were not reported consistently.
Published reports of Ae. aegypti and Ae. albopictus occurrence are recorded in S3 Table and
mapped by country in Fig 3. Ae. aegypti occurrence was reported in 11 MENA countries and
historically (i.e. prior to 1960) in Algeria, Libya, Morocco, Syria, and Tunisia. Ae. albopictus
was reported in seven MENA countries, including Algeria, Palestine, and Syria, countries
where Ae. aegypti is not currently reported. No published reports of Ae. aegypti or Ae. albopic-
tus occurrence (or DENV outbreaks) were identified in seven MENA countries: Bahrain, Iran,
Iraq, Jordan, Kuwait, Qatar, and United Arab Emirates. Since 2005, Ae. aegypti and/or Ae.
albopictus occurrence has been documented in Afghanistan, Algeria, Lebanon, Oman, Pales-
tine, Syria, and Turkey, though autochthonous transmission of DENV has not yet been
reported from these countries.
Fig 2. Geographic distribution of human prevalence studies and reported outbreaks of dengue in the Middle East and North Africa.
doi:10.1371/journal.pntd.0005194.g002
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Table 4. Summary of human prevalence studies for dengue virus in the Middle East and North Africa (n = 103).*
Study characteristics General population (n = 42) n (%) Acute febrile illness (n = 23) n (%) Suspected dengue (n = 38) n (%)
Total sample size 24,377 4,065 33,955
Median DENV % prevalence (range %) 25% (0–61.9) 15.2% (0–87.5) 47.4% (6.8–100)
Year of study
before 1990 21 (50%) 7 (30%) 0
1990 to 2015 21 (50%) 16 (70%) 38 (100%)
Study setting
community 31 (74%)† 2 (9%) 2 (5%)
clinic or hospital 11 (26%) 21 (91%) 36 (95%)
Assay
ELISA IgG 19 (45%) 8 (35%) 10 (26%)
ELISA IgM 11 (26%) 17 (74%) 31 (82%)
immunofluorescence antibody 5 (12%) 2 (9%) 2 (5%)
hemagglutination inhibition 15 (36%) 5 (22%) 2 (5%)
complement fixation 1 (2%) 1 (4%) 0
viral neutralization 2 (5%) 1 (4%) 0
PCR 0 4 (17%) 14 (37%)
cell culture 0 3 (13%) 1 (3%)
NS1 antigen 2 (5%) 0 1 (3%)
Assay make
in-house 21 (50%) 10 (43%) 11 (29%)
commercial 20 (48%) 10 (43%) 15 (39%)
not specified 1 (2%) 3 (13%) 12 (32%)
Target protein**
whole virus 32 (76%) 12 (52%) 6 (16%)
envelope 7 (17%) 4 (17%) 9 (24%)
not specified 3 (7%) 7 (30%) 21 (55%)
Risk of bias summary
Assay
low risk of bias 2 (5%) 8 (35%) 14 (37%)
high risk of bias 40 (95%) 15 (65%) 24 (63%)
unclear risk of bias 0 0 1 (3%)
Sampling methodology
low risk of bias 15 (36%) n/a n/a
high risk of bias 17 (40%) n/a n/a
unclear risk of bias 10 (24%) n/a n/a
Response rate
low risk of bias 6 (14%) 11 (48%) 22 (58%)
high risk of bias 1 (3%) 0 0
unclear risk of bias 35 (83%) 12 (52%) 16 (42%)
Precision
High 28 (67%) 15 (65%) 28 (74%)
Low 14 (33%) 8 (35%) 10 (26%)
* N = 103 because the study type (i.e. general prevalence, acute febrile illness, or suspected dengue) was not specified in two studies [51, 57].
†Community study settings also include animal quarantine station (n = 1), blood donation center (n = 5), military (n = 3), and university (n = 1).
** Indicates the target protein for the initial screening assay for studies in which multiple diagnostic assays were utilized.
doi:10.1371/journal.pntd.0005194.t004
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Discussion
Our study offers an assessment of published prevalence, incidence, and outbreak reports per-
taining to the epidemiology of dengue in the MENA region. Based on the study results, the
MENA contains two apparent subregions known to harbor DENV: 1) Pakistan, and 2) the Red
Sea countries (Djibouti, Egypt, Saudi Arabia, Somalia, Sudan, and Yemen). No seroprevalence
or outbreak data was identified across broad areas of the MENA, however, including some
Aedes endemic areas. There was also a paucity of reports estimating human incidence and vec-
tor infection rates. These findings suggest priorities for future research. However, they also
Table 5. Summary of human incidence studies for dengue virus in the Middle East and North Africa (n = 3).
Country,
Ref.
Year
(s) of
study
Duration
of follow-
up
City or
governorate
Setting;
population(age
range, years)
Study
design
Sampling Assay
type
Assay
make+
Assay
Target
Serotype
tested
Sample
size
Incidence
Pakistan (n = 1)
Siddiqui
[41]
1999–
2001
1999–
2001
Karachi Urban slum;
children <16
years of age with
undifferentiated
febrile illness
CS Active
surveillance
ELISA
IgM
Diag.
Auto.
wv 1–4 1,248 185/
100,000
Sudan (n = 2)
Seidahmed
[39]
2008–
09
12
months
Port Sudan
City
Urban
community;
general pop.
living in houses
where DENV-
carrying
mosquitoes were
present (<1–80)
Pros.
coh
RSS ELISA
IgM
PanBio Env 1–4 791 35/10,000
Seidahmed
[40]
2010 17 weeks Port Sudan Urban
community;
general pop.
CS Conv. ELISA
IgM,
NS1,
PCR
n/s n/s n/s 3,765‡ 94/10,000
‡ Reported cases
Abbreviations: CS, cross-sectional; ELISA, enzyme-linked immunosorbent assay; Env, envelope; PCR, polymerase chain reaction; Pros. coh, prospective
cohort; RSS, random stratified sampling
Assay Abbreviation: Diag. Auto. (Diagnostic Automation, CA, USA); PanBio (Brisbane, Australia)
doi:10.1371/journal.pntd.0005194.t005
Table 6. Summary of vector infection rate studies for dengue virus in the Middle East and North Africa (n = 3)
Author,
Ref.
Year(s) of data
collection
City or
governorate
Setting Mosquito
species
Assay
type
Sample size Infection
rate
Comments
Pakistan
Jahan
[42]
2011 Lahore Urban areas Ae. aegypti Ag-capture
ELISA
114 pools
(n = 570
mosquitoes)
27.2%
Ae.
albopictus
Ag-capture
ELISA
4 pools (n = 20
mosquitoes)
25%
Yemen
Zayed
[43]
2010–11 Al Hodayda houses of CHIKV
cases at Eritrean
refugee camp
Ae. aegypti RT-PCR 11 pools (n = 30
mosquitoes)
0% 17 Culex spp.
mosquitoes were also
negative for DENV RNA.
Abbreviations: RT-PCR, reverse transcription-polymerase chain reaction
doi:10.1371/journal.pntd.0005194.t006
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challenge efforts to synthesize and compare the inter- and intra-country epidemiology of
DENV in the region.
Dengue seroprevalence in the MENA
In our review, Pakistan reported the highest number of prevalence studies and the broadest
study coverage among MENA countries. Multiple studies reported >20% prevalence in both
general population and those with undifferentiated AFI [1, 106, 122–124]. DENV serotypes
1–4 are known to circulate in Pakistan, unlike other MENA countries [82]. Pakistan also
reported the largest number of confirmed cases among all DENV outbreaks in the MENA,
with 21,580 cases reported during the 2011 DENV-2 outbreak [79, 120] (S2 Table).
In the Red Sea region, multiple general population and AFI population IgG seroprevalence
measures exceeding 20% were published from in Djibouti, Saudi Arabia, Somalia, Sudan, and
Yemen within the past decade (Table 3) along with multiple confirmed outbreaks of DENV
serotypes 1–3 since the 1980s (S2 Table). DENV-4 has not yet been identified in this subregion
to our knowledge. Although reported outbreaks and cases often localize along the Red Sea
coastline in these countries [1], seroprevalence studies suggest a broader distribution of DENV
infections that are likely underdetected (Fig 2). This is illustrated by the sentinel report of a
DENV-infected traveler returning from Yemen in 1983 [125], despite the first outbreaks of
DENV in Yemen and Saudi Arabia not being reported until 1994 [126–128]. Our search also
identified no published prevalence studies or outbreaks in Egypt after 1969 until a dengue out-
break was reported in November 2015 [10]. However, DENV transmission was suggested
years prior by a report of two travelers diagnosed with dengue after returning from southern
Fig 3. Country-level distribution of Aedes aegypti and Aedes albopictus occurrence in the Middle East and North Africa.
doi:10.1371/journal.pntd.0005194.g003
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Egypt in 2011 [129] and the identification of Ae. aegypti in southern Egypt that same year
[130]. It is plausible that undetected DENV transmission had been occurring in Egypt prior to
this outbreak. However, it is not clear whether this and other recent outbreaks represent
increasing incidence, increasing detection, or both, amidst the heterogeneity in study coverage
and reporting in the MENA.
Clinical and methodological diversity among studies
An important finding in our study was the clinical and methodological diversity among
DENV prevalence studies. This diversity represents a challenge to synthesizing the epidemio-
logic literature for DENV in the MENA. Clinically, studies represented a diversity of human
populations of different ages and demographics, in different years, and different locations and
transmission contexts. Ninety-six percent of studies from Afghanistan, Pakistan, Saudi Arabia,
Somalia, and Yemen were conducted during or prior to 1990. However, 53% of studies in
other MENA countries were conducted prior to 1990, when study methods and DENV epide-
miology may have been different. Methodologically, most studies utilized convenience samples
without reporting response rates, entailing high risk of bias and uncertainty in the representa-
tiveness of reported measures (Table 4). These findings, along with the high variability in
regional study coverage, precluded meta-analyses of the available data.
Flavivirus cross-reactivity
Serologic cross-reactions remain a challenge to seroepidemiologic studies for DENV and other
flaviviruses. Viral neutralization tests, considered the gold standard serologic assay for DENV,
were performed in only 5% of general population seroprevalence studies in our review. Com-
pared to ELISAs, seroprevalence measures were 22–86% lower by secondary/confirmatory
testing with immunofluorescence or VNT in our review [14, 36, 37, 113]. This illustrates the
potential uncertainty surrounding the reliability of ELISAs in DENV serologic studies, particu-
larly in areas where the prevalence of antigenically similar viruses is broad or unknown. West
Nile virus (WNV), for example, is thought to be distributed across the MENA on account of
its ubiquitous Culex spp. vector and migratory bird flyways [131–133]. With up to 80% of
WNV infections occurring subclinically, the potential for serologic cross-reactions with
DENV antibody assays must be considered. Yellow fever vaccine-derived and natural antibod-
ies may also cross-react with anti-DENV antibodies, especially relevant in YFV endemic
regions such as Sudan [38, 107, 111]. As the emergence of zika virus in the Western Hemi-
sphere or the re-emergence of YFV has shown, serologic assays with low specificity are inade-
quate to tackle the epidemiologic challenges of emerging arboviral diseases [134].
Heterogeneity in dengue outbreak reports
Our review identified DENV outbreaks in over a third of MENA countries, with most out-
breaks reported from Pakistan, Sudan, and Saudi Arabia (S2 Table). Outbreaks varied widely
across time and space in the MENA: reported cases varied from <10 to>100,000 over a span
of months to years, reported from the village level to the level of the province and region. This
presents a challenge to epidemiologic monitoring and policy planning for DENV, as use of dif-
ferent outbreak definitions results in differences in early detection and response [30]. There is
currently no consensus on how to define DENV outbreaks, and adopting a common definition
for the MENA is challenging given the region’s heterogeneous infection pressures, multiple
DENV serotypes, and variable surveillance and detection capacity. At present, assessing
whether a reported transmission event in the MENA significantly deviates from baseline trans-
mission, and thus constitutes an outbreak, is often unclear.
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Risk factors and research priorities
Our study did not identify confirmed DENV transmission in any of the MENA countries west
of Egypt and east of Saudi Arabia until Pakistan (Fig 2). However, the paucity of published
data in these sub-regions does not preclude the possibility of unrecognized transmission in
some areas or the risk of emergence in others. Indeed, modeling studies suggest ecologic
niches for Aedes along the coastal Mediterranean Basin of North Africa [1, 123, 135], and Ae.
albopictus and/or Ae. aegypti has been recently reported in Algeria, Lebanon, Palestine, Syria,
and Turkey [5, 136–140] (Fig 3 and S3 Table). In contrast, Ae. albopictus has been identified
along the Mediterranean coast of Europe for decades along with local transmission of DENV
and chikungunya since 2007 [141]. Near the Pakistan border, serologic evidence suggests pos-
sible DENV transmission in Iran [14, 51, 53] and Afghanistan [44], though local transmission
has not been confirmed to our knowledge [53]. The presence of Aedes or DENV transmission
in these areas should not be ruled out [53].
Several ecologic and social factors in the MENA may promote the spread of Aedes-borne
viruses like DENV. Urbanization [142] may increase the risk of outbreaks and use of open water
storage containers that promote Ae. aegypti breeding [1, 39, 43, 55, 95, 111, 123, 135]. Heavy rain-
fall has been implicated in DENV outbreaks in Sudan, Djibouti, and Yemen [12, 47, 143, 144],
which may become increasingly unpredictable through climate change [145]. Armed conflicts and
economic turmoil in Iraq, Syria, and Yemen may render these areas vulnerable to vector-borne
diseases while diminishing surveillance and response [146]. Inter-regional migration poses risk for
imported DENV, as millions of migrants travel from DENV-endemic countries to the Arabian
Peninsula [111, 126, 146–149] and to Mecca, Saudi Arabia to attend Umra and Hajj [126]. Intra-
regionally, heavy commerce in the Red Sea region likely drives DENV serotype mixing and spread
[116, 148], as evidenced by multiple DENV outbreaks occurring at port cities in Djibouti [37, 45],
Saudi Arabia [126], Sudan [39], and Yemen [116, 148]. Contiguous spread of DENV from Yemen
to Oman [150], or from Pakistan to Iran or Afghanistan [14], may also pose risk.
A number of research priorities emerge concerning the epidemiology of DENV in the
MENA. First, broader seroepidemiologic coverage in the region is needed. Such studies are
efficient means of characterizing infection pressures in populations lacking surveillance and
diagnostic capacity. Multiplexed diagnostics are increasingly available and are well-suited for
concurrently exploring the distribution other undercharacterized arboviruses in the region
(e.g. Alkhumra, Chikungunya, Crimean-Congo Hemorrhagic Fever, O’Nyong-nyong, Rift
Valley Fever, Sandfly Fever virus complex, Usutu, and West Nile viruses). Second, serologic
studies should include methods to minimize cross-reactions, particularly for flaviviruses [151].
Third, seroepidemiologic studies should incorporate uniformity in study design and enroll-
ment criteria to minimize confounding, such as standard case definitions for studies of ‘sus-
pected’ dengue [126]. Ideally this could include population-based sampling that provides
baseline data to benchmark the regional impact of these pathogens over the coming years.
Fourth, studies should incorporate vector surveillance and infection rates. Such studies are
important for understanding transmission dynamics that inform vector control strategies and
predict future transmission and disease risk [123, 135, 141]. Guidelines and tools for calculat-
ing vector infection rates are available [141, 152]. Finally, attaining a meaningful definition of
DENV outbreaks in the MENA countries will require a thorough assessment of baseline sur-
veillance, control, and treatment capacities in endemic regions [30].
Study limitations
Our study was limited by its reliance on select databases of peer-reviewed literature screened
by one investigator with the exclusion of grey literature which may have provided additional
Dengue in the MENA
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005194 December 7, 2016 22 / 31
data. Reviewing other Aedes-transmitted pathogens or studies reporting Aedes distribution in
the MENA may also have provided further insights regarding the potential geographic distri-
bution of DENV. Due to the limitations in the content and distribution of studies, we did
not perform a meta-analysis nor did we explore bias in overall outcome measures through a
funnel plot or Egger test. Non-publication of studies with small or zero effect size or studies
targeted to known dengue-endemic areas may have biased the distribution and quantity
of DENV studies. The prevalence measures themselves may have been biased through sero-
logic-cross reactions, targeting of older study populations (with higher seroprevalence),
and lack of convalescent titers for acute DENV infection studies (possibly underestimating
seroprevalence).
Conclusions
DENV seroprevalence in the MENA is high among some populations in the Red Sea region and
Pakistan, while recent outbreaks in these subregions suggest increasing DENV incidence driven
by ecologic and social factors. Published prevalence and incidence, vector occurrence, and vector
infection rates are lacking in broad areas of the MENA and available studies contain methodo-
logical limitations. These findings illustrate the need to strengthen programs for surveillance,
reporting, and control of DENV and Aedes in the MENA, both to define DENV and Aedes epi-
demiology and to mitigate the risk of emerging Aedes-transmitted pathogens in the future.
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